Stay updated with breaking news from Narcolepsy Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In The US. The biotechnology sector in the United States is witnessing a surge […]
In a decade, Christophe Weber remade Takeda into a global pharma leader, shifting from a fragmented structure to a unified innovator.
Takeda TSE4502NYSETAK today announced positive topline results from a randomized doubleblind placebocontrolled multiple dose Phase 2b trial evaluating TAK861 an oral orexin receptor 2 OX2R agonist in patients with narcolepsy type 1.
− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial− TAK-861 Was Found to be Generally Safe and Well-Tolerated− Results Will be Presented at an Upcoming Scientific CongressOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline resu...
October 25, 2023 Alkermes Q3 2023 Earnings Conference Call Prepared Remarks Sandy Coombs: Welcome to the Alkermes plc...